BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.57
+6.44%Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.12
- EPS estimate
- —
- Revenue actual
- $76.2K
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- —
- EPS misses (12Q)
- —
- EPS in line (12Q)
- —
- Avg surprise (4Q)
- —
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | — | -$0.12 | — | $76.2K |
| May 15, 2026 | — | -$0.23 | — | $22.8K |
| Nov 14, 2025 | — | -$0.39 | — | $2.5M |
| Aug 18, 2025 | — | -$0.34 | — | $2.3M |
| May 15, 2025 | — | -$0.03 | — | $2.1M |
| Nov 15, 2024 | — | -$0.20 | — | $2.6M |
| Aug 14, 2024 | — | $0.10 | — | $2.0M |
| May 31, 2024 | — | -$0.11 | — | $2.8M |
| Mar 29, 2024 | — | $0.17 | — | $2.3M |
| Nov 20, 2023 | — | -$0.20 | — | $2.6M |
| Nov 14, 2022 | — | -$0.05 | — | $2.6M |
| Aug 15, 2022 | — | -$0.10 | — | $2.5M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Aug 14, 2026